181 related articles for article (PubMed ID: 37453183)
1. Treat-to-target in real-life psoriatic arthritis patients: achieving minimal disease activity with bDMARDs/tsDMARDs and potential barriers.
Ortolan A; Lorenzin M; Cozzi G; Scagnellato L; Favero M; Striani G; Vio S; Scapin V; De Conti G; Doria A; Ramonda R
Semin Arthritis Rheum; 2023 Oct; 62():152237. PubMed ID: 37453183
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study.
Haroon M; Ahmad M; Baig MN; Mason O; Rice J; FitzGerald O
Arthritis Res Ther; 2018 Apr; 20(1):73. PubMed ID: 29665824
[TBL] [Abstract][Full Text] [Related]
3. Axial spondyloarthritis and axial psoriatic arthritis: similar or different disease spectrum?
Benavent D; Plasencia-Rodríguez C; Franco-Gómez K; Nieto R; Monjo-Henry I; Peiteado D; Balsa A; Navarro-Compán V
Ther Adv Musculoskelet Dis; 2020; 12():1759720X20971889. PubMed ID: 33240404
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
Lubrano E; Parsons WJ; Perrotta FM
J Rheumatol; 2016 May; 43(5):918-23. PubMed ID: 26980581
[TBL] [Abstract][Full Text] [Related]
5. Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis.
Iannone F; Nivuori M; Fornaro M; Venerito V; Cacciapaglia F; Lopalco G
Rheumatology (Oxford); 2020 Jul; 59(7):1599-1606. PubMed ID: 31652315
[TBL] [Abstract][Full Text] [Related]
6. Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis.
Wervers K; Vis M; Tchetveriko I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Luime JJ
Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1764-1770. PubMed ID: 29609220
[TBL] [Abstract][Full Text] [Related]
7. Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff.
Alves de Oliveira Junior H; Pereira da Veiga T; Acurcio FA; Almeida AM; Ribeiro Dos Santos JB; da Silva MRR; Kakehasi AM; Cherchiglia ML
Hosp Pract (1995); 2020 Oct; 48(4):213-222. PubMed ID: 32567403
[TBL] [Abstract][Full Text] [Related]
8. Residual Disease Burden in Patients With Axial Spondyloarthritis and Psoriatic Arthritis Despite Low Disease Activity States in a Multiethnic Asian Population.
Liu V; Fong W; Kwan YH; Leung YY
J Rheumatol; 2021 May; 48(5):677-684. PubMed ID: 33132217
[TBL] [Abstract][Full Text] [Related]
9. Platelet to albumin ratio is an independent indicator for disease activity in ankylosing spondylitis.
Cui R; Wang YL; Tao YL; Tong Q; Chen Z; Dai SM
Clin Rheumatol; 2023 Feb; 42(2):407-413. PubMed ID: 36414863
[TBL] [Abstract][Full Text] [Related]
10. Dactylitis Is Associated With More Severe Axial Joint Damage and Higher Disease Activity in Axial Psoriatic Arthritis.
Li SS; Du N; He SH; Liang X; Li TF
J Rheumatol; 2022 Sep; 49(9):1012-1019. PubMed ID: 35501145
[TBL] [Abstract][Full Text] [Related]
11. Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study.
Luchetti Gentiloni MM; Paci V; Carletto A; Zabotti A; Ramonda R; Chimenti MS; Dagna L; Luciano N; Piccinelli A; Giovannini I; Striani G; Boffini N; Sandri G; Possemato N; Pantano I; Benfaremo D; Salvarani C; Ciccia F; Selmi C; Moroncini G
Arthritis Res Ther; 2023 Oct; 25(1):196. PubMed ID: 37821952
[TBL] [Abstract][Full Text] [Related]
12. Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial).
Uhrenholt L; Schlemmer A; Hauge EM; Christensen R; Dreyer L; Suarez-Almazor ME; Kristensen S
BMJ Open; 2019 Jul; 9(7):e028517. PubMed ID: 31292181
[TBL] [Abstract][Full Text] [Related]
13. The value of SPARCC sacroiliac MRI scoring in axial psoriatic arthritis and its association with other disease parameters.
Gezer HH; Duruöz MT
Int J Rheum Dis; 2022 Apr; 25(4):433-439. PubMed ID: 35080124
[TBL] [Abstract][Full Text] [Related]
14. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
Lubrano E; De Socio A; Perrotta FM
J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
[TBL] [Abstract][Full Text] [Related]
16. The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials.
Denis A; Sztejkowski C; Arnaud L; Becker G; Felten R
RMD Open; 2023 Jul; 9(3):. PubMed ID: 37507210
[TBL] [Abstract][Full Text] [Related]
17. Achievement rate and predictive factors of the recommended therapeutical target in patients with axial spondyloarthritis who remain on biological therapy: a prospective cohort study in Spain.
Benavent D; Franco-Gómez K; Plasencia-Rodriguez C; Novella-Navarro M; Bogas P; Nieto R; Monjo I; Nuño L; Villalba A; Peiteado D; Balsa A; Navarro-Compán V
BMJ Open; 2022 Apr; 12(4):e057850. PubMed ID: 35487753
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.
Lorenzin M; Ortolan A; Cozzi G; Calligaro A; Favaro M; Del Ross T; Doria A; Ramonda R
Clin Rheumatol; 2021 Nov; 40(11):4569-4580. PubMed ID: 34136971
[TBL] [Abstract][Full Text] [Related]
19. Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?
Maksymowych WP; Inman RD; Bessette L; Rahman P; Rampakakis E; Asin-Milan O; Rachich M; Marrache AM; Lehman AJ
Arthritis Res Ther; 2023 Apr; 25(1):70. PubMed ID: 37118833
[TBL] [Abstract][Full Text] [Related]
20. Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry.
Prior-Español A; Sánchez-Piedra C; Campos J; Manero FJ; Pérez-García C; Bohórquez C; Busquets-Pérez N; Blanco-Madrigal JM; Díaz-Torne C; Sánchez-Alonso F; Mateo L; Holgado-Pérez S
Sci Rep; 2021 May; 11(1):11091. PubMed ID: 34045525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
